Table 6.
Effect of treatment with Agarikon Plus, Agarikon.1 and 5-fluorouracil in various combinations on MMP-2 and MMP-9 levels in serum supernatant of mice bearing CT26.WT tumors.
| Experimental Group | MMP-2 (ng/mL) | MMP-9 (ng/mL) |
|---|---|---|
| Control | 245.01 ± 26.72 | 201.49 ± 33.06 |
| AP | 232.69 ± 7.29 | 284.76 ± 50.42 |
| AP + 5-FU | 264.38 ± 30.03 | 180.90 ± 43.38 |
| AG.1 | 285.25 ± 38.71 | 260.02 ± 28.52 |
| AG.1 + 5-FU | 331.19 ± 20.81 ** | 155.16 ± 36.30 |
| AP + AG | 294.87 ± 10.03 | 206.62 ± 4.54 |
| AP + AG + 5-FU | 270.51 ± 20.13 | 179.86 ± 34.39 |
| 5-FU | 292.66 ± 36.79 | 164.38 ± 44.93 |
Mice were injected s.c. with CT26.WT (1 × 106/mouse) cells and treated. Mice were sacrificed on day 28 post tumor cell inoculation and MMP-2 and MMP-9 levels in serum supernatant were measured by ELISA kit (Chongqing Biospes Co., Ltd., Biospes, China) according to the manufacturer’s instructions. Values are the means ± SD. * Significantly different (** p < 0.01) in comparison with control group.